Morgan Stanley Upgrades Hikma Pharmaceuticals Plc (HIK) to Overweight
Hikma Pharmaceuticals Plc (LON:HIK) was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating in a research note issued on Tuesday. The firm presently has a GBX 2,200 ($27.49) price target on the stock, down from their previous price target of GBX 2,500 ($31.23). Morgan Stanley’s price target points to a potential upside of 26.95% from the stock’s current price.
Other analysts also recently issued reports about the stock. Numis Securities Ltd initiated coverage on shares of Hikma Pharmaceuticals Plc in a report on Friday, July 22nd. They set an “add” rating and a GBX 2,830 ($35.36) price objective for the company. Jefferies Group lifted their price objective on shares of Hikma Pharmaceuticals Plc from GBX 2,800 ($34.98) to GBX 2,990 ($37.36) and gave the stock a “buy” rating in a report on Tuesday, July 26th. HSBC dropped their price objective on shares of Hikma Pharmaceuticals Plc from GBX 1,985 ($24.80) to GBX 1,800 ($22.49) and set a “hold” rating for the company in a report on Friday, November 11th. Citigroup Inc. downgraded shares of Hikma Pharmaceuticals Plc to a “neutral” rating and set a GBX 2,600 ($32.48) price objective for the company. in a report on Thursday, August 4th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Hikma Pharmaceuticals Plc from GBX 2,550 ($31.86) to GBX 2,450 ($30.61) and set an “overweight” rating for the company in a report on Wednesday, September 14th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of GBX 2,337.40 ($29.20).
Shares of Hikma Pharmaceuticals Plc (LON:HIK) opened at 1674.00 on Tuesday. The firm’s 50-day moving average is GBX 1,880.03 and its 200-day moving average is GBX 2,198.23. The company’s market cap is GBX 3.78 billion. Hikma Pharmaceuticals Plc has a 12 month low of GBX 1,575.00 and a 12 month high of GBX 2,703.00.
In other news, insider Al-Husry,Ali acquired 140,000 shares of the firm’s stock in a transaction on Wednesday, August 31st. The shares were purchased at an average price of GBX 2,150 ($26.86) per share, for a total transaction of £3,010,000 ($3,760,619.69). Also, insider Said Darwazah acquired 50,000 shares of the firm’s stock in a transaction on Monday, September 26th. The stock was purchased at an average price of GBX 2,078 ($25.96) per share, for a total transaction of £1,039,000 ($1,298,100.95).
Hikma Pharmaceuticals Plc Company Profile
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.
Receive News & Stock Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related stocks with our FREE daily email newsletter.